Welcome to our dedicated page for Hong Kong Pharma news (Ticker: HKPD), a resource for investors and traders seeking the latest updates and insights on Hong Kong Pharma stock.
Hong Kong Pharma Digital Technology Holdings Ltd (NASDAQ: HKPD) operates at the intersection of pharmaceutical distribution and cross-border e-commerce, specializing in OTC products through its dual-division structure. This page provides investors and stakeholders with timely updates on regulatory developments, supply chain innovations, and strategic partnerships shaping Asia's healthcare logistics landscape.
Access consolidated updates on HKPD's Supply Chain Services via Joint Cross Border and Procurement & Distribution operations through V-Alliance. Track critical announcements including earnings disclosures, compliance milestones, and cross-border expansion initiatives affecting Mainland China-Hong Kong pharmaceutical trade flows.
Key updates cover regulatory approvals, logistics network expansions, and OTC product portfolio developments. Our news collection serves as a centralized hub for monitoring operational efficiencies in complex pharmaceutical supply chains and digital integration advancements.
Bookmark this page for structured access to HKPD's latest business developments. Check regularly for authoritative updates on cross-border e-commerce solutions and compliance-driven distribution strategies in the OTC pharmaceutical sector.
Hong Kong Pharma Digital Technology (NASDAQ: HKPD) reported strong financial results for H1 2024 (ended September 30), with net revenues reaching $11.09 million, up 58.9% year-over-year. The growth was primarily driven by:
- Supply Chain Services revenue: $6.33M (+36.3% YoY)
- Procurement and Distribution: $4.76M (+102.7% YoY)
- Consignment Sales: $2,210 (down from $15,327)
The company's gross profit increased 42.6% to $1.91M, while total expenses rose to $10.07M. Despite higher costs, net income surged 232.6% to $828,559, demonstrating operational efficiency and successful market expansion in the OTC pharmaceutical cross-border e-commerce sector.
Hong Kong Pharma Digital Technology Holdings (NASDAQ: HKPD), a leading OTC pharmaceutical cross-border e-commerce supply chain services provider in Hong Kong, has completed its initial public offering. The company sold 1,403,685 ordinary shares at $4.00 per share, comprising 1,000,000 shares from the company and 403,685 from selling shareholders.
The IPO generated total gross proceeds of $5,614,740, with the company receiving $4,000,000 and selling shareholders receiving $1,614,740, before deducting underwriting costs. Trading began on Nasdaq Capital Market on January 15, 2025, under 'HKPD'. The company granted underwriters a 45-day option to purchase up to 150,000 additional shares.
The net proceeds will fund development of supply chain ERP systems, warehouse equipment procurement, sales and marketing team expansion, and working capital needs. Bancroft Capital led the underwriting, with Eddid Securities USA as co-underwriter.
